Bridges Investment Management Inc. Has $1.08 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Bridges Investment Management Inc. grew its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 98.9% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 12,070 shares of the medical equipment provider's stock after buying an additional 6,001 shares during the period. Bridges Investment Management Inc.'s holdings in Lantheus were worth $1,080,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC grew its stake in Lantheus by 7.7% in the third quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider's stock valued at $393,844,000 after acquiring an additional 257,022 shares during the period. Geode Capital Management LLC increased its position in shares of Lantheus by 2.0% in the third quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock worth $184,798,000 after purchasing an additional 32,551 shares during the last quarter. Reinhart Partners LLC. grew its position in Lantheus by 9.9% during the fourth quarter. Reinhart Partners LLC. now owns 1,366,873 shares of the medical equipment provider's stock valued at $122,280,000 after acquiring an additional 123,282 shares during the last quarter. Swedbank AB lifted its stake in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider's stock worth $99,054,000 after acquiring an additional 385,000 shares during the period. Finally, Portolan Capital Management LLC lifted its position in Lantheus by 6.1% during the third quarter. Portolan Capital Management LLC now owns 670,881 shares of the medical equipment provider's stock valued at $73,629,000 after buying an additional 38,776 shares during the period. Institutional investors own 99.06% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

LNTH has been the topic of several research reports. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. JMP Securities reaffirmed a "market outperform" rating and set a $112.00 price target on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective for the company. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $132.86.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the sale, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. The trade was a 10.76 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James H. Thrall sold 1,000 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.50% of the company's stock.

Lantheus Stock Down 1.0 %

Shares of Lantheus stock traded down $1.03 on Thursday, hitting $99.45. 430,561 shares of the company were exchanged, compared to its average volume of 900,192. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The stock has a market capitalization of $6.81 billion, a price-to-earnings ratio of 16.51 and a beta of 0.44. The company has a 50-day moving average price of $90.29 and a 200 day moving average price of $96.78.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to analysts' expectations of $376.61 million. Research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.